Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

syahrir maulana In my previous Aquestive Therapeutics (NASDAQ:AQST) article, I discussed how the company was approaching a significant milestone with the impending topline data readout for their Anaphylm (AQST-109) epinephrine sublingual film anticipated in Q1 of this year. At that time, the company had already initiated patient dosing in their Phase III pivotal study to evaluate Anaphylm’s pharmacokinetics (PK) and pharmacodynamics (PD) with the potential of a New Drug Application (NDA) filing in 2024. ...